Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00357604 · ClinicalTrials.gov registry record · Phase 1
Atazanavir and Ritonavir (ATV/RTV) and an Oral Contraceptive in Healthy Females
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT00357604 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 22 participants.
The verdict
NCT00357604, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
The purpose of this study is to administer a combined oral contraceptive (ethinyl estradiol and norgestimate) with the HIV treatment of atazanavir and ritonavir to healthy females in order to assess if the concentrations of the oral contraceptive change. The safety of this treatment regimen will also be studied.
Interventions
- DRUG Ortho Tri-Cyclen (ethinyl estradiol + norgestimate)
- DRUG Ortho Tri-Cyclen LO (ethinyl estradiol + norgestimate) + Atazanavir/Ritonavir for 14 days then Ortho Tri-Cyclen for 7 days
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2006-07 |
| Est. Completion | 2006-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00357604
The ClinicalTrials.gov registry entry for NCT00357604 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ortho Tri-Cyclen (ethinyl estradiol + norgestimate) is the first listed.
NCT00357604 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00357604 about?
NCT00357604 is a clinical study titled "Atazanavir and Ritonavir (ATV/RTV) and an Oral Contraceptive in Healthy Females". The purpose of this study is to administer a combined oral contraceptive (ethinyl estradiol and norgestimate) with the HIV treatment of atazanavir and ritonavir to healthy females in order to assess if the concentrations of the oral contraceptive change. The safety of this treatment regimen will als...
What is the current status of trial NCT00357604?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2006-07. Estimated completion is 2006-11.
What interventions are being tested in trial NCT00357604?
The interventions under investigation include: Ortho Tri-Cyclen (ethinyl estradiol + norgestimate) (DRUG), Ortho Tri-Cyclen LO (ethinyl estradiol + norgestimate) + Atazanavir/Ritonavir for 14 days then Ortho Tri-Cyclen for 7 days (DRUG).
Who is sponsoring clinical trial NCT00357604?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.